Metabolic Syndrome, Cardiovascular Disease, and the Hair Growth Cycle: Addressing Hair Growth Disruptions Using Nourkrin with Marilex as a Proteoglycan Replacement Therapy: A Concise Review

The review from May 22, 2018, explored the link between metabolic syndrome, cardiovascular disease, and hair growth disruptions, particularly androgenetic alopecia (AGA). It found that alopecia is associated with an increased risk of coronary heart disease, hypertension, hyperinsulinemia, insulin resistance, and metabolic syndrome, with the severity of alopecia correlating with the risk of coronary heart disease. However, the relationship between AGA and metabolic syndrome was not definitively established. The authors suggested that AGA could be an early marker of metabolic syndrome and recommended early screenings and lifestyle changes to reduce associated risks. The review also reported on the effectiveness of Nourkrin® with Marilex®, a proteoglycan replacement therapy, in promoting hair growth. A double-blind placebo-controlled trial showed a 35.7% increase in hair count over 6 months, indicating the therapy's significant effect on hair growth.